Type 2 Diabetes Mellitus
Conditions
Interventions
Sponsors
Tianjin Metabolic Diseases Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. New diagnosis of type 2 diabetes (new diagnosis of type 2 diabetes: a history of no diabetes, no hypoglycemic treatment, and reached the diagnostic criteria for type 2 diabetes in the past 1 year). 2. Male or female, older than 18 years old. 3. HbA1c was between 7.5% and 10.5% in the early screening, and HbA1c was between 7.0% and 10.5% before the start of the visit. 4. Fasting blood glucose is less than 13.3mmol/L. 5. BMI between 18.5kg/m2 and 45.0kg/m2. 6. Fasting C-peptide level is greater than 0.33nmol / L. 7. Voluntary participation and cooperation in research and signing informed consent.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant or planning to become pregnant, breastfeeding or have a fertility willingness in the near future; 2. Patients with pacemakers, neurostimulators, artificial metal heart valves, etc.; 3. Patients with aneurysm clip; 4. There are intraocular metal foreign bodies, inner ear implants, metal prostheses, metal joints, and ferromagnetic foreign bodies in the body; 5. Severe hyperthermia patients; 6. Patients with epilepsy or claustrophobia or who cannot cooperate with nuclear magnetic examination; 7. Patients with severe diabetic complications such as diabetic ketoacidosis, hyperosmolar hyperglycemia syndrome, lactic acidosis, etc.; 8. Patients with unstable glycemic control who must use insulin to control blood sugar; 9.Blood lipids are significantly elevated, fasting triglycerides are greater than 9.3mmol / L; 10. Abnormal liver function, ALT or AST is more than 3 times the upper limit of normal (based on laboratory results 1 month before the experiment); 11. Acute myocardial infarction, cerebrovascular accident and severe infection occurred within 6 months prior to enrollment; 12. Glomerular filtration rate <60 ml / min / 1.73m2 (based on laboratory test results 1 month before the experiment); 13. Previous diagnosis of heart failure, myocardial infarction or percutaneous coronary intervention; 14. Previously used or currently treated with SGLT-2i; 15. Allergic to SGLT-2i, lactose or acarbose; 16. Have poorly controlled hypertension; blood pressure systolic blood pressure greater than 180mmHg, systolic blood pressure greater than 110 mmHg; 17. Previous gastrointestinal disease or surgical history, including intestinal obstruction, intestinal ulcer, weight loss surgery or banding surgery, gastrointestinal anastomosis, intestinal resection; 18. History of previous immunocompromised or malignant tumors; 19. Use of glucocorticoids and other drugs that affect blood sugar; 20. Currently using loop diuretics; 21. Patients with a history of mental illness, who have not followed the research plan and are conducting research tasks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal RBF (blood flow per 100 grams of tissue per minute);Measuring the oxygenation status of kidney tissue;Diffusion movement in renal tissue;Fat quantitative measurement;Glycated hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in fasting blood glucose;Postprandial blood glucose change;BMI change;Change in systolic blood pressure; | — |
Countries
China
Contacts
Public ContactPei Yu
Tianjin Metabolic Diseases Hospital
Outcome results
None listed